Whales with a lot of money to spend have taken a noticeably bullish stance on Regeneron Pharmaceuticals. Looking at options history for Regeneron Pharmaceuticals (NASDAQ:REGN) we detected 10 trades.
Investor's Business Daily on MSN10d
Regeneron Pharmaceuticals Beats On Libtayo's Back, Unveils DividendRegeneron stock rose early Tuesday on a strong fourth-quarter report that included in-line sales of eye drug Eylea.
We note that Sanofi records global net product sales of Dupixent and Kevzara, while Regeneron records its share of profits/losses in connection with the global sales of both drugs. Dupixent’s ...
Country Manager (Oncology), Regeneron Canada; Justin Holko, Senior Vice President, Global Oncology/Hematology Commercial Business Unit, Regeneron; Acher Elfassy, Country Manager (Immunology ...
Regeneron posted Q4 adjusted EPS of $12.07 ... and full year 2024 compared to the same periods of 2023. LLibtayo’s global net sales increased by 50% to $367 million. Sanofi collaboration ...
Country Manager (Oncology), Regeneron Canada; Justin Holko, Senior Vice President, Global Oncology/Hematology Commercial Business Unit, Regeneron; Acher Elfassy, Country Manager (Immunology), ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback